Immunotherapy Esophagus Cancer
1 clinical trials · Condition
◉ Watch Immunotherapy Esophagus Cancer
| Record | Firm | Date |
|---|---|---|
| Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma (NCT05515315) | Fuzhou General Hospital | 2022-05-31 |
Track Immunotherapy Esophagus Cancer automatically
Every clearance here is in the API, with alerts when new ones post.